Pharma BD Deal Intelligence
Eli Lilly adds preclinical Alzheimer's candidate through USD 1b deal with AlzeCure. ACD680 remains preclinical with no clinical data generated; Lilly assumes…
AlzeCure Pharma Soars on Major Eli Lilly Alzheimer Deal. AlzeCure shares jumped 301.4% after announcing the partnership granting Lilly global rights to…
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement. The deal includes $10 million upfront and more than $990 million in potential development and…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AlzeCure Pharma entered a global collaboration and out-licensing agreement granting Eli Lilly worldwide rights to Alzstatin ACD680, a preclinical oral gamma-secretase modulator for Alzheimer's disease, announced June 9, 2026. AlzeCure receives $10 million upfront and is eligible for milestone payments exceeding $1 billion plus tiered mid-single-digit royalties. ACD680 modulates amyloid processing to lower aggregation-prone Abeta42, adding an oral small-molecule approach to Lilly's neuroscience pipeline. Closing is subject to Swedish foreign-direct-investment clearance.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / AlzeCure Pharma AB (this deal) | 2026 | $1.0B | 54 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2026 deals · Eli Lilly and Company deals · Neurology deals